万古霉素治疗严重MRSA感染的治疗药物监测:修订版共识指南执行摘要
该执行摘要由美国卫生系统药师协会、美国感染病学会、儿科感染病学会和感染病药师学会联合制定,基于近期万古霉素PK/PD和毒效学研究,重新评估 dosing 和监测策略。指南推荐以AUC/MIC(肉汤微量稀释法,假设MIC为1 mg/L时AUC/MIC 400-600)作为严重MRSA感染的目标,并采用AUC引导的给药和监测以优化疗效与安全性。
要点
- AUC/MIC是万古霉素最合适的PK/PD目标,替代谷浓度监测。
- 严重MRSA感染目标为AUC/MIC(BMD法)400-600(假设MIC=1 mg/L)。
- AUC引导的给药和监测是最准确和优化的管理方式。
核心结论
- 对于严重MRSA感染,推荐AUC/MIC(BMD法)400-600(假设MIC=1 mg/L)作为疗效目标,同时改善安全性。
- AUC引导的给药和监测是管理万古霉素治疗最准确和优化的方法。
研究设计与样本
- 由美国卫生系统药师协会、美国感染病学会、儿科感染病学会和感染病药师学会联合制定。
主要发现
- 近期PK/PD研究确定AUC/MIC为最合适的PK/PD目标。
- 2009年指南推荐谷浓度作为AUC/MIC的替代标志物,但近期毒效学研究报道谷浓度监测与肾毒性增加相关。
关键数值与推荐
- 目标AUC/MIC(BMD法)为400-600(假设MIC_BMD为1 mg/L)。
临床怎么用
- 临床应使用AUC引导的给药和监测来优化万古霉素治疗严重MRSA感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent vancomycin PK/PD and toxicodynamic studies enable a reassessment of the current dosing and monitoring guideline in an attempt to further optimize the efficacy and safety of vancomycin therapy. The area-under-the-curve to minimum inhibitory concentration (AUC/MIC) has been identified as the most appropriate pharmacokinetic/pharmacodynamic (PK/PD) target for vancomycin. The 2009 vancomycin consenus guidelines recommended specific trough concentrations as a surrogate marker for AUC/MIC. However, more recent toxicodynamic studies have reported an increase in nephrotoxicity associated with trough monitoring. METHODS AND RESULTS: This is the executive summary of the new vancomycin consensus guidelines for dosing and monitoring vancomycin therapy and was developed by the American Society of Health-Systems Pharmacists, Infectious Diseases Society of America, Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists vancomycin consensus guidelines committee. CONCLUSIONS: The recommendations provided in this document are intended to assist the clinician in optimizing vancomycin for the treatment of invasive MRSA infections in adult and pediatric patients. An AUC/MIC by broth microdilution (BMD) ratio of 400 to 600 (assuming MICBMD of 1 mg/L) should be advocated as the target to achieve clinical efficacy while improving patient safety for patients with serious MRSA infections. In such cases, AUC-guided dosing and monitoring is the most accurate and optimal way to manage vancomycin therapy.
引用
- Rybak MJ, Le J, Lodise TP, et al. Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2020. PMID: 32227354. doi:10.1002/phar.2376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。